Table 2.

Ongoing phase 3 trials on anti-amyloid therapy in AD in 2019

Agent	Mechanism of action	Target type and therapeutic purpose	ClinicalTrials.gov identifier	Status
Plasma exchange with albumin 1 immunoglobulin	Plasma exchange	Remove amyloid	NCT01561053	Completed
ALZT-OP1a + ALZT-OP1b	Mast cell stabilizer, anti-inflammatory	Amyloid-related and antineuroinflammatory	NCT02547818	Active, not recruiting
ANAVEX2–73	Anti-tau, Anti-amyloid	Anti-tau, anti-amyloid, and antineuroinflammatory	NCT03790709	Recruiting
Crenezumab	Monoclonal antibody directed at oligomers	Remove amyloid	NCT02670083.NCT03114657.NCT03491150	Completed
E2609 (elenbecestat)	BACE inhibitor	Reduce amyloid production	NCT02956486.NCT03036280	Active, not recruiting
Gantenerumab	Monoclonal antibody	Remove amyloid	NCT02051608.NCT01224106.NCT03444870.NCT03443973	NCT02051608.NCT01224106 Active, not recruiting, NCT03444870.NCT03443973 Recruiting
Gantenerumab and Solanezumab	Monoclonal antibody	Remove amyloid/reduce amyloid production	NCT01760005	Recruiting
GV-971 (sodium oligomannurarate)	Aβ aggregation inhibitor	Amyloid-related	NCT02293915	Completed
Solanezumab	Monoclonal antibody	Remove amyloid and prevent aggregation	NCT02008357	Active, not recruiting